Clinical trials: Monoclonal Gammopathy of Undetermined Significance
Schnitzler Syndrome, Urticarial Vasculitis With Monoclonal Immunoglobulin M Component, Schnitzler (Disorder)
Study of the Efficacy and Safety of RPH-104 in Adult Subjects With Schnitzler Syndrome
The primary goal of the study is to assess the efficacy and safety of RPH-104 in subjects with Schnitzler Syndrome using Schnitzler Disease Activity Score (SDAS), which includes the Physician's Global Assessment (PGA) and the…
- Trial name
- NCT04213274
- Testing
- 80 mg RPH-104
- Where
- 4 sites in United States
- Sponsor
- R-Pharm Overseas, Inc.
Pruritus, Monoclonal Gammopathy
Frequency and Characteristics of Pruritus in Patients With Monoclonal Gammopathy
Pruritus is most often secondary to dermatitis but can also occur without skin lesions, it is called pruritus sine materia. The causes of pruritus sine materia are various: haematological (myeloproliferative neoplasia ...)…
- Trial name
- PRURIGAMMA (NCT03832140)
- Where
- France
- Volunteers
- 281 people
- Sponsor
- University Hospital, Brest
Multiple Myeloma, Monoclonal Gammopathy of Undetermined Significance
The China M-protein Screening Project in First-degree Relatives of Myeloma Patient - The CHAPERONE Study
The goal of the China Monoclonal Gammopathy Screening Project in First-degree Relatives of Patients With Multiple Myeloma (CHAPERONE) study is to assess the clinical significance of screening for monoclonal gammopathy (M-protein)…
- Trial name
- CHAPERONE (NCT05965115)
- Testing
- Sample of Blood
- Where
- China
- Volunteers
- 10,000 people
- Sponsor
- Shanghai Zhongshan Hospital
Monoclonal Gammopathy of Undetermined Significance
Iceland Screens, Treats or Prevents Multiple Myeloma
This study will assess the benefits and harms of screening for monoclonal gammopathy of undetermined significance (MGUS). The overall and disease-specific mortality will be compared between screened and not screened participants.
- Trial name
- iStopMM (NCT03327597)
- Testing
- Clinical follow-up 1, Mental Health and Quality of Life questionnaire, Standard follow-up or treatment.
- Where
- Iceland
- Volunteers
- 80,761 people, healthy volunteers welcome
- Sponsor
- University of Iceland
Schnitzler Syndrome
Ilaris® Effects in Schnitzler Syndrome (ILESCH)
This is a multi-center double-blind placebo-controlled study to assess the efficacy and safety of canakinumab (trade name Ilaris®), a high-affinity monoclonal antibody that neutralizes IL-1β, in patients with Schnitzler syndrome.
- Trial name
- ILESCH (NCT01390350)
- Testing
- Canakinumab
- Where
- 5 sites in Germany
- Volunteers
- 20 people
- Sponsor
- Charite University, Berlin, Germany
Chronic Myeloproliferative Disorders, Leukemia
Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment
RATIONALE: Antiemetic drugs, such as ondansetron, may help to reduce or prevent nausea and vomiting in patients with advanced cancer.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00006348
- Testing
- ondansetron
- Where
- 12 sites in United States
- Volunteers
- 100 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Chronic Myeloproliferative Disorders, Leukemia
Treatment for Chronic Pain in Patients With Advanced Cancer
RATIONALE: Different drug formulations and combinations of drugs may help patients with chronic pain live more comfortably. It is not yet known which regimen is most effective for chronic pain.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00003687
- Testing
- dextromethorphan hydrobromide, morphine sulfate
- Where
- 4 sites in Canada
- Volunteers
- 87 people
- Sponsor
- NCIC Clinical Trials Group
Leukemia, Lymphoma
PS-341 in Treating Patients With Advanced Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of PS-341 in treating patients who have advanced cancer.
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Precancerous Condition
- Trial name
- NCT00006362
- Testing
- bortezomib
- Where
- 2 sites in United States
- Sponsor
- Mayo Clinic
Schnitzler Syndrome
Efficacy and Safety of Canakinumab in Schnitzler Syndrome
Schnitzler syndrome is a disabling inflammatory disease, characterized by chronic urticaria, fever, arthralgia, bone pain and gammopathy, which can so far only be effectively treated with anakinra, an interleukin-1 receptor…
- Trial name
- NCT01276522
- Testing
- Canakinumab
- Where
- Netherlands
- Volunteers
- 8 people
- Sponsor
- Radboud University Medical Center
Anemia, Metastatic Cancer
Proteases in Patients With Prostate Cancer That Has Spread to the Bone
RATIONALE: Collecting and storing samples of bone marrow and tissue from patients to test in the laboratory may help the study of cancer.
- Conditions
- Anemia, Metastatic Cancer, Myelodysplastic Syndromes, Precancerous Condition
- Trial name
- NCT00899665
- Testing
- fluorescence in situ hybridization, microarray analysis, molecular diagnostic method
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Waldenstrom Macroglobulinemia
Non-invasive Diagnostics and Monitoring of MRD and Clonal Evolution in Waldenström's Macroglobulinemia and in IgM-MGUS
Multicenter retrospective and prospective observational study including patients with WM or IgM-MGUS evaluated at the time of diagnosis and during the disease course using highly sensitive techniques.
- Trial name
- FIL_BIOWM (NCT03521596)
- Testing
- MRD and clonal evolution
- Where
- 15 sites in Italy, Spain
- Volunteers
- 300 people
- Sponsor
- Fondazione Italiana Linfomi - ETS
Plasma Cell Dyscrasias
The Indiana Myeloma Registry
This is a prospective, non-interventional, observational study. The purpose of this study is to collect data and bio-specimens that will support future research
- Trial name
- NCT03616483
- Testing
- This is a non-interventional trial
- Where
- United States
- Volunteers
- 2,500 people
- Sponsor
- Indiana University
Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
S0334 Analyzing Chromosomes in Patients With Newly Diagnosed Multiple Myeloma or Other Blood Disease
RATIONALE: Studying the chromosomes in samples of bone marrow and blood in the laboratory from patients with cancer or other blood diseases may help doctors learn more about the disease.
- Conditions
- Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Precancerous/Nonmalignant Condition
- Trial name
- NCT00898066
- Testing
- cytogenetic analysis, fluorescence in situ hybridization
- Volunteers
- 37 people
- Sponsor
- SWOG Cancer Research Network
Multiple Myeloma and Plasma Cell Neoplasm, Precancerous Condition
Beta Alethine in Treating Patients With Myeloma
RATIONALE: Biological therapies such as beta alethine use different ways to stimulate the immune system and stop cancer cells from growing.
- Trial name
- NCT00006466
- Testing
- beta alethine
- Where
- 3 sites in United States
- Sponsor
- LifeTime Pharmaceuticals
Immune System Diseases, Autoimmune Diseases
Clonal Hematopoiesis of Immunological Significance
Ambispective, national, multicenter observational cohort study aimed at characterizing the satellite dysimmune manifestations of clonal hematopoiesis, including Vexas (Vacuoles, E1 enzyme, X-linked, Autoinflammatory and Somatic)…
- Conditions
- Immune System Diseases, Autoimmune Diseases, Inflammation, Autoinflammatory Diseases
- Trial name
- CHIS (NCT05969821)
- Testing
- observational cohort study
- Where
- France
- Volunteers
- 5,000 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Cancer
Natural History Study of Fungal Infections of the Blood in Patients With Cancer or in Patients Who Have Undergone a Stem Cell Transplant
RATIONALE: Gathering information about how often fungal infections of the blood occur in patients with cancer or in patients who have undergone stem cell transplant may help doctors learn more about the disease.
- Trial name
- NCT00445952
- Testing
- clinical observation, management of therapy complications
- Where
- 5 sites in Belgium, France and 3 more
- Volunteers
- 304 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Multiple Myeloma, Monoclonal Gammopathy of Undetermined Significance
Early Detection of Multiple Myeloma to Fight Cancer Disparities: A Screening and Patient Navigation Program
This project will pilot the expansion of the existing Taussig Outreach Program's community outreach and patient navigation model to study the multiple myeloma (MM) screening program.
- Conditions
- Multiple Myeloma, Monoclonal Gammopathy of Undetermined Significance, Smoldering Multiple Myeloma
- Trial name
- NCT05831358
- Testing
- Multiple Myeloma M-Protein Analysis, Multiple Myeloma Knowledge Questionnaires
- Where
- United States
- Volunteers
- 201 people, healthy volunteers welcome
- Sponsor
- Case Comprehensive Cancer Center
Kidney Failure, Paraproteinemias
The Effect of Daratumumab in Patients With Monoclonal Gammopathy of Renal Significance (MGRS) in Finland
The goal of this clinical trial is to learn if drug daratumumab works to treat kidney diseases other than AL-amyloidosis that fall under the category of monoclonal gammopathy of renal significance (MGRS).
- Conditions
- Kidney Failure, Paraproteinemias, Glomerulonephritis
- Trial name
- DAMOCLES (NCT06889948)
- Testing
- Daratumumab
- Where
- Finland
- Volunteers
- 30 people
- Sponsor
- Helsinki University Central Hospital
Chronic Myeloproliferative Disorders, Leukemia
Interleukin-2 Plus Interferon Alfa in Treating Adults With Metastatic Cancer
RATIONALE: Interleukin-2 may stimulate a person's white blood cells to kill metastatic cancer cells. Interferon alfa may interfere with the growth of the cancer cells.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00002504
- Testing
- aldesleukin, recombinant interferon alfa
- Where
- 5 sites in United States
- Sponsor
- Hoag Memorial Hospital Presbyterian
Monoclonal Gammopathy of Renal Significance
Daratumumab, Bortezomib, Cyclophosphamide, and Dexamethasone Therapy for Patients with MIDD
This is an open-label, multicenter, Phase 2 study in subjects with newly diagnosed monoclonal immunoglobulin deposition disease treated with daratumumab, bortezomib, cyclophosphamide, and dexamethasone.
- Trial name
- NCT06418477
- Testing
- Dara-CyBorD
- Where
- 3 sites in China
- Volunteers
- 20 people
- Sponsor
- Peking University People's Hospital